20 July 2026
In plain English
The FDA's peptide advisory panel meets Wednesday. Days before, the FDA's own scientists published their review — and they recommend against letting specialty pharmacies custom-make all seven of the experimental drugs called peptides (short protein fragments used for recovery and longevity) up for a vote, including BPC-157, the most talked-about one. That reverses Barque. We had been betting the panel would overrule its own staff and wave BPC-157 through. But the documents that would make that case — presentations from peptide advocates — never appeared on the public record, and the panel looks like its usual membership, not a stacked one. So we flip: BPC-157 most likely does NOT get the green light Wednesday. Everything else — the Medicare weight-loss program, weight-loss drug economics — is quiet.
Signal detail
Confirmed staff-against-all-7 was already priced (BofA raised Hims's PT to $36 while flagging FDA opposition as tempering peptide optionality). Hims has run its OneTwenty compounded-peptide offering 13+ weeks with zero enforcement and keeps an active Instagram peptide-education campaign live — its launch-first, retreat-under-enforcement pattern is intact. Horizon is Dec 31. A denial Wednesday marginally raises delay risk but doesn't break the thesis. Holding.
The FDA's own materials — insufficient safety data plus unassessed immunogenicity across all seven — are citation-ready ammunition for an investigative feature during the July 23–30 regulatory convergence week. No top-5 outlet has run a feature-length peptide-injury investigation yet. 254 days to resolution. Holding.
— Day 20, physician-gated quiet ramp, no enrollment data, zero consumer search demand in GSC. First pharmacy claims data expected late July. Holding.
— First-party Katalys logged 0 conversions / $0 this week (clicks +11%, GSC impressions −44% w/w); reads as attribution lag and traffic volatility, not a thesis change. Still zero peptide DTC affiliates in-network; staff-against-all-7 further delays any compliant peptide affiliate surface. Holding.
Resolutions & upcoming
Nothing resolved today.
Resolving Wednesday, July 23 (T-3): - `bpc157-pcac-2026` — now 0.72 (72% does NOT get the permitted list / 28% it does). Reversed today. - `pcac-july-multi-peptide` — now 0.35 (35% ≥2 of 4 get the permitted list). Reversed today.
Both flagged for operator review before the vote. Day-2 peptides (emideltide/DSIP, Semax, Epitalon) are also on the FDA's against-list but are not the subject of a Barque forecast. All other forecasts resolve December 2026 or later.
How Barque got smarter today
- The briefing document is the event, not the vote. Ra held 0.35 for many consecutive runs, then reversed +0.37 in a single day — that is the system working, not whipsaw. The distinction that matters: reversing on the FDA's own published staff review is signal; reversing on creator chatter would be noise. Codify: for any advisory-committee forecast, the release of FDA background materials (T-2) is a scheduled, high-weight update point that should be anticipated, not reacted to late.
- Absence held as evidence, then confirmed. Last week's premortem flagged the missing advocate oral presentations and said to push BPC-157 back toward 0.40 "if still absent." They are still absent — and the briefing docs arrived negative on top. The absence was correctly read as evidence, not noise. Good calibration of a weak signal.
- Separate "institutional mechanics" from "panel philosophy" — and don't over-weight the philosophy until confirmed. The 0.35 over-indexed on an assumed pro-peptide panel that a roster check could not confirm. Failure mode caught: I let a vivid political narrative (Kennedy reconstitutes the panel) override the base rate for weeks without hard confirmation of the mechanism. The base rate deserved more weight sooner.
- Quiet is quiet. Four of six forecasts unmoved; the Medicare bridge and affiliate-mix theses are behaving exactly as modeled. No manufactured motion.